Vaccine trains immune system to hunt down cancer cells
NCT ID NCT05101356
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial tests a vaccine called LabVax 3(22)-23, designed to help the immune system recognize and attack a protein called labyrinthin found on adenocarcinoma tumor cells. The study includes adults with advanced or metastatic adenocarcinoma and will evaluate the vaccine alone or combined with the immunotherapy drug pembrolizumab. The goal is to see if the vaccine is safe and can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LabVax 3(22)-23 (cancer vaccine), sargramostim (GM-CSF), and pembrolizumab
- What this could lead to
- If successful, this approach could offer a new treatment option for advanced adenocarcinomas by training the immune system to attack tumor cells.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the vaccine may not prove effective or may cause side effects. Combining it with pembrolizumab could increase immune-related adverse events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can AI be a Pathologist's second opinion?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Could MRI replace CT for sharper cancer radiation planning?
- Blood tests could unlock early clues for three major lung diseases
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers